S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ATYR · aTyr Pharma, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$0.17
-0.00
(-0.06%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$0.17
$0.17
$0.18
52-WEEK RANGE
$0.17
$0.17
$1.11
What's happening
- ATYR is down 0.06% today, trading at $0.17. — Live quote
- It's trading within 3% of its 52-week low ($0.17). (Finnhub fundamentals)
- Volume today (30,790) is well below its 3-month average of 2,953,600. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.11 actual vs. $-0.12 estimated (+11.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 6
Hold 6
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ATYR
-78.07%
vs S&P 500
-90.47%
1-YEAR RETURN
ATYR
-83.17%
vs S&P 500
-98.53%
6-MONTH RETURN
ATYR
-79.63%
3-MONTH RETURN
ATYR
-64.70%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.11
Est. $-0.12
BEAT +11.2%
2026-04-26 (Q1 2026)
$-0.11
Est. $-0.14
BEAT +21.6%
2026-01-26 (Q4 2025)
$-0.14
Est. $-0.19
BEAT +25.3%
2025-10-26 (Q3 2025)
$-0.26
Est. $-0.19
MISS -38.8%
Valuation Measures & Ratios
Enterprise Value4$1.3M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)89.21
Price / Book71.20
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin-13549.47%
Operating Margin-14076.32%
Return on Equity (ROE8)-99.62%
Return on Assets (ROA9)-74.41%
Avg Volume (3M)2,953,600
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $57.1M | $76.2M | $71.4M | $449.2M | $263.5M |
| P/E | -0.86 | -1.07 | -0.92 | -6.61 | -4.12 |
| Price/Sales | — | — | 375.89 | — | 1121.12 |
| Price/Book | 1.17 | 1.31 | 0.89 | 6.00 | 3.51 |
| EV/Revenue | — | — | 343.53 | — | 1077.03 |
| EV/EBITDA | -0.60 | -0.90 | -0.81 | — | — |
| ROE | -136.05% | -122.46% | -96.48% | -90.82% | -85.19% |
| ROA | -95.06% | -89.07% | -72.59% | -66.95% | -65.75% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short12,893,008
Change from Prior Settlement+20.86%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -55.1% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -13549.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is -83.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ATYR
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $190.0K | $0 | $0 | $0 | $0 | $235.0K |
| Operating income | -$10.9M | -$11.4M | -$26.7M | -$20.3M | -$15.8M | -$18.1M | -$17.3M | -$16.6M |
| Net income | -$10.3M | -$10.8M | -$25.7M | -$19.5M | -$14.9M | -$17.3M | -$16.3M | -$15.5M |
| EPS (diluted) | $-0.11 | $-0.11 | $-0.26 | $-0.22 | $-0.17 | $-0.23 | $-0.23 | $-0.23 |
| EPS (basic) | $-0.11 | $-0.11 | $-0.26 | $-0.22 | $-0.17 | $-0.23 | $-0.23 | $-0.23 |
| Operating margin | — | — | -$14.1K | — | — | — | — | -$7.1K |
| Net margin | — | — | -$13.5K | — | — | — | — | -$6.6K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $69.8M | $79.7M | $93.0M | $106.7M | $101.5M | $97.2M | $96.8M | $91.6M |
| Stockholders' equity | $48.8M | $57.9M | $67.5M | $80.2M | $74.8M | $75.0M | $70.0M | $65.3M |
| Total current assets | $58.4M | $67.6M | $80.2M | $93.0M | $87.5M | $83.3M | $82.0M | $76.3M |
| Total current liabilities | $11.4M | $11.7M | $15.1M | $15.7M | $15.5M | $10.7M | $15.0M | $14.1M |
| Cash & equivalents | $16.2M | $10.0M | $10.7M | $6.2M | $17.2M | $10.4M | $11.1M | $11.5M |
| Marketable securities (current) | — | — | — | $79.0M | — | — | — | — |
| Marketable securities (non-current) | — | — | — | $5.1M | — | — | — | — |
| Property, plant & equipment | $4.1M | $4.2M | $4.3M | $4.4M | $4.5M | $4.7M | $4.8M | $5.0M |
| Other non-current assets | $190.0K | $148.0K | $148.0K | $149.0K | $66.0K | $66.0K | $66.0K | $130.0K |
| Accounts payable | $3.2M | $2.8M | $3.9M | $4.1M | $3.9M | $1.5M | $4.3M | $3.9M |
| Accrued liabilities | $6.7M | $7.5M | $9.8M | $10.2M | $10.3M | $7.9M | $9.4M | $9.0M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $98.0K | $98.0K | $98.0K | $98.0K | $93.0K | $89.0K | $84.0K | $76.0K |
| Retained earnings | -$627.3M | -$617.0M | -$606.2M | -$592.2M | -$566.5M | -$546.9M | -$532.0M | -$517.1M |
| Accumulated other comprehensive income (loss) | -$68.0K | -$70.0K | -$8.0K | -$1.0K | -$75.0K | -$66.0K | -$40.0K | $36.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.4M | -$12.5M | -$12.2M | -$20.5M | -$13.9M | -$15.4M | -$13.1M | -$13.2M |
| Investing cash flow | $15.3M | $11.5M | $16.4M | -$20.4M | $3.3M | -$4.4M | -$6.1M | $17.9M |
| Financing cash flow | -$129.0K | -$142.0K | -$131.0K | $29.6M | $17.9M | $18.6M | $18.8M | -$105.0K |
| Free cash flow | -$9.4M | -$12.7M | -$12.2M | -$20.5M | -$13.9M | -$15.4M | -$13.2M | -$13.2M |
| Capital expenditures | $73.0K | $138.0K | $31.0K | $37.0K | $9.0K | $0 | $25.0K | $15.0K |
| Depreciation & amortization | $168.0K | $162.0K | $166.0K | $165.0K | $166.0K | $167.0K | $175.0K | $178.0K |
| Share-based compensation | — | — | — | — | — | — | — | — |
| Purchases of investments | $8.0M | $5.9M | $12.8M | $39.3M | $18.2M | $23.1M | $26.1M | $2.9M |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $190.0K | $235.0K | $353.0K | $10.4M | $0 |
| Operating income | -$77.6M | -$67.9M | -$54.9M | -$46.4M | -$34.0M |
| Net income | -$74.1M | -$64.0M | -$50.4M | -$45.3M | -$33.8M |
| EPS (diluted) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 |
| EPS (basic) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 |
| Operating margin | -$40.9K | -$28.9K | -$15.6K | -$447 | — |
| Net margin | -$39.0K | -$27.2K | -$14.3K | -$437 | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $93.0M | $96.8M | $120.7M | $95.8M | $115.5M |
| Stockholders' equity | $67.5M | $70.0M | $90.7M | $71.5M | $109.3M |
| Total current assets | $80.2M | $82.0M | $103.0M | $80.9M | $113.6M |
| Total current liabilities | $15.1M | $15.0M | $16.4M | $13.9M | $6.0M |
| Cash & equivalents | $10.7M | $11.1M | $22.5M | $10.0M | $2.3M |
| Marketable securities (current) | — | — | — | — | — |
| Marketable securities (non-current) | — | — | — | — | — |
| Property, plant & equipment | $4.3M | $4.8M | $5.5M | $3.1M | $543.0K |
| Other non-current assets | $148.0K | $66.0K | $131.0K | $193.0K | $158.0K |
| Accounts payable | $3.9M | $4.3M | $3.5M | $3.1M | $1.0M |
| Accrued liabilities | $9.8M | $9.4M | $11.6M | $9.9M | $4.0M |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | — | — | — | — | — |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $98.0K | $84.0K | $63.0K | $29.0K | $28.0K |
| Retained earnings | -$606.2M | -$532.0M | -$468.0M | -$417.6M | -$372.3M |
| Accumulated other comprehensive income (loss) | -$8.0K | -$40.0K | -$74.0K | -$433.0K | -$263.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$62.0M | -$69.1M | -$33.2M | -$41.9M | -$33.1M |
| Investing cash flow | -$5.1M | $17.2M | -$20.1M | $47.2M | -$91.6M |
| Financing cash flow | $66.0M | $39.9M | $66.2M | $5.5M | $110.0M |
| Free cash flow | -$62.1M | -$69.2M | -$37.4M | -$43.5M | -$33.3M |
| Capital expenditures | $77.0K | $65.0K | $4.2M | $1.6M | $192.0K |
| Depreciation & amortization | $664.0K | $708.0K | $592.0K | $232.0K | $475.0K |
| Purchases of investments | $93.4M | $69.1M | $107.0M | $42.1M | $126.5M |
| Debt repaid | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ATYR as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-02-03 to 2026-05-27
Recent transactions
- Insiders have net bought 100,000 shares over the last 182 days, across 1 purchase and 0 sales.
- Most recent: SCHIMMEL PAUL (Reporting person) — Open market purchase of 100,000 shares on 2026-05-27.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)100,000 sh(1 txns)
Sales (open market)0 sh(0 txns)
Net Shares+100,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| SCHIMMEL PAUL | Reporting person | Open market purchase | 2026-05-27 | 100,000 |
| Shukla Sanjay | President and CEO | Open market sale | 2026-02-04 | 3,745 |
| Broadfoot Jill Marie | Chief Financial Officer | Open market sale | 2026-02-04 | 1,558 |
| DENYES NANCY | General Counsel | Open market sale | 2026-02-04 | 1,118 |
| Gross Jane A | Reporting person | Open market purchase | 2025-03-17 | 3,750 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-27 | SCHIMMEL PAUL | Reporting person | Open market purchase | 100,000 | $0.50 |
| 2026-02-04 | Shukla Sanjay | President and CEO | Open market sale | 3,745 | $0.98 |
| 2026-02-04 | Broadfoot Jill Marie | Chief Financial Officer | Open market sale | 1,558 | $0.98 |
| 2026-02-04 | DENYES NANCY | General Counsel | Open market sale | 1,118 | $0.98 |
| 2026-02-03 | Shukla Sanjay | President and CEO | Option exercise | 10,375 | — |
| 2026-02-03 | Broadfoot Jill Marie | Chief Financial Officer | Option exercise | 3,750 | — |
| 2026-02-03 | DENYES NANCY | General Counsel | Option exercise | 2,687 | — |
| 2025-10-09 | SCHIMMEL PAUL | Reporting person | Open market purchase | 317,999 | $0.94 |
| 2025-10-08 | SCHIMMEL PAUL | Reporting person | Open market purchase | 682,001 | $0.90 |
| 2025-03-17 | Gross Jane A | Reporting person | Open market purchase | 3,750 | $4.00 |
| 2025-02-04 | Broadfoot Jill Marie | Chief Financial Officer | Open market sale | 1,254 | $3.78 |
| 2025-02-04 | DENYES NANCY | General Counsel | Open market sale | 899 | $3.78 |
| 2025-02-03 | Shukla Sanjay | President and CEO | Option exercise | 10,375 | — |
| 2025-02-03 | Broadfoot Jill Marie | Chief Financial Officer | Option exercise | 3,750 | — |
| 2025-02-03 | DENYES NANCY | General Counsel | Option exercise | 2,687 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:34 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 8-K | 2026-10-16 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-24 | 8-K | 2026-09-24 | View on SEC.gov → |
| 2026-08-07 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-07 | 8-K | 2026-08-07 | View on SEC.gov → |
| 2026-07-31 | 8-K | 2026-07-30 | View on SEC.gov → |
| 2026-06-08 | 8-K | 2026-06-03 | View on SEC.gov → |
| 2026-06-01 | 8-K | 2026-06-01 | View on SEC.gov → |
| 2026-05-28 | 4 | 2026-05-27 | View on SEC.gov → |
| 2026-05-15 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-15 | 8-K | 2026-05-15 | View on SEC.gov → |
| 2026-05-13 | 4 | 2026-05-11 | View on SEC.gov → |
Recent news
Headlines about ATYR (aTyr Pharma, Inc.). Links open the publisher — we don’t host full articles.
-
aTyr Pharma, Inc. (ATYR) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
aTyr Pharma stock gains 185.71 percent versus Frankfurt close
AD HOC NEWS · 2026-10-20 -
ATYR Oct 2026 1.000 call (ATYR261016C00001000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-20 -
ATyr Pharma shares drop about 3.5% after breaking well below key moving averages
Traders Union · 2026-10-19 -
aTyr Pharma partners with Einstein on cancer research By Investing.com
Investing.com South Africa · 2026-10-19 -
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
Yahoo · 2026-10-19 -
About 1,000 U.S. children and teens are diagnosed yearly with a common bone cancer. aTyr will study an antibody.
Stock Titan · 2026-10-19 -
aTyr Pharma Enters Research Collaboration With Albert Einstein College Of Medicine To Develop And Test ATYR2810, Its Monoclonal Antibody That Targets The Neuropilin-2 Receptor
Benzinga · 2026-10-19
No headlines in this category right now — try “All”.